Board Meeting Details

The Board of Directors meeting was held on Tuesday, 26th May 2026, commencing at 11:00 AM and concluding at 01:00 PM.

Key Approvals and Disclosures

Financial Results Approval:

  • Approved audited Standalone and Consolidated Financial Results for quarter and year ended 31st March 2026
  • Auditor's report signed by PSV Jain & Associates, Statutory Auditor
  • Declaration of unmodified opinion in Audit Report

Internal Auditor Appointment:

  • Appointed M/s NP Rajput & Co, Chartered Accountants as Internal Auditor for Financial Year 2026-27
  • Appointment date: 26th May 2026
  • Term: Financial Year 2026-27
  • Qualification: Wide experience in Income tax Compliances, GST compliances, Accounting, Internal Audit, GST audit

Standalone Financial Performance (INR in lakhs)

Quarter Ended 31st March 2026:

  • Revenue from operations: ₹1,590.35
  • Other income: ₹45.44
  • Total revenue: ₹1,635.79
  • Total expenses: ₹1,486.46
  • Profit before tax: ₹149.33
  • Tax expense: ₹36.93 (Current tax: ₹34.72, Deferred tax: ₹2.21)
  • Net profit after tax: ₹112.39
  • Basic EPS: ₹0.80
  • Diluted EPS: ₹0.74

Year Ended 31st March 2026:

  • Revenue from operations: ₹4,212.68
  • Other income: ₹212.93
  • Total revenue: ₹4,425.61
  • Total expenses: ₹3,954.31
  • Profit before tax: ₹471.30
  • Tax expense: ₹113.18 (Current tax: ₹104.93, Deferred tax: ₹8.25)
  • Net profit after tax: ₹358.11
  • Basic EPS: ₹2.60
  • Diluted EPS: ₹2.54

Comparative Performance:

  • Q4 FY26 net profit increased 25% from ₹90.10 lakhs in Q4 FY25
  • FY26 annual net profit more than doubled from ₹174.08 lakhs in FY25

Capital Structure Changes

  • Allotted 6,25,000 Equity Shares of face value ₹10 each at issue price of ₹55 per share (including premium of ₹45 per share)
  • Allotted 29,50,000 Warrants convertible into equivalent Equity Shares at ₹55 per warrant (including premium of ₹45 per warrant)
  • 25% consideration received on application for warrants
  • Paid-up equity share capital: ₹1,434.59 lakhs (31st March 2026) vs ₹1,376.27 lakhs (31st March 2025)

Standalone Balance Sheet (31st March 2026, INR in lakhs)

  • Total assets: ₹8,279.17
  • Current assets: ₹3,845.41 (Inventories: ₹397.24, Trade receivables: ₹1,889.13, Cash: ₹1,355.16)
  • Equity: ₹6,749.86 (Share capital: ₹1,434.59, Other equity: ₹4,900.65, Money against warrants: ₹405.63)
  • Liabilities: ₹1,529.31

Consolidated Financial Performance (INR in lakhs)

Quarter Ended 31st March 2026:

  • Revenue from operations: ₹1,833.98
  • Other income: ₹12.95
  • Total revenue: ₹1,846.93
  • Net profit after tax: ₹149.72
  • Profit attributable to shareholders: ₹130.01
  • Basic EPS: ₹0.93
  • Diluted EPS: ₹0.86

Year Ended 31st March 2026:

  • Revenue from operations: ₹5,270.66
  • Other income: ₹97.28
  • Total revenue: ₹5,367.94
  • Net profit after tax: ₹532.47
  • Profit attributable to shareholders: ₹449.63
  • Basic EPS: ₹3.26
  • Diluted EPS: ₹3.19

Strategic Acquisition

  • Acquired 31.68% stake in SSM Formulations Private Limited on 23rd March 2026
  • SSM Formulations now classified as Associate Company
  • Accounted using Equity Method from 23rd March 2026
  • No material allocable share of profit/loss recognized for the period

Segment Reporting

The Group operates under two reportable segments:

1. Speciality Chemicals & Pharma Intermediates

2. Logistics Services (commenced operations during current financial year)

Segment Revenue FY26 (INR in lakhs):

  • Speciality Chemicals: ₹4,602.75
  • Logistics Services: ₹667.90
  • Total: ₹5,270.66

Segment Results FY26 (INR in lakhs):

  • Speciality Chemicals: ₹323.40
  • Logistics Services: ₹121.25
  • Total: ₹444.65

Entities Included in Consolidation

  • Eiko LifeSciences Limited (Parent)
  • Eiko Scientific Solutions LLP (Wholly Owned LLP)
  • Eikovivify Logistics Private Limited (Subsidiary)
  • Reflux Pharmaceuticals Private Limited (Associate Company)
  • SSM Formulations Private Limited (Associate Company)